Oncology

As of 22 July, 2024

Product Name	Mechanism	Target Disease	Development Stage					Country / Region	Licensor
			1	2	3	Filing	Approval
ONO-4059	BTK inhibitor	Primary central nervous system lymphoma						JP・KR・TW	In-house
								US
		Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma						JP
ONO-7475	Axl/Mer inhibitor	Pancreatic cancer ★						JP	In-house
		EGFR mutation-positive non-small cell lung cancer						JP
ONO-4685	PD-1 x CD3 bispecific antibody	T-cell lymphoma						JP・US	In-house
ONO-4578	PG receptor (EP4) antagonist	Gastric cancer ★						JP・KR・TW	In-house
		Colorectal cancer ★						JP
		Pancreatic cancer ★						JP
		Non-small cell lung cancer ★						JP
		Hormone receptor-positive, HER2-negative breast cancer						JP
ONO-7914	STING agonist	Solid tumor ★						JP	In-house
ONO-7018	MALT1 Inhibitor	Non-Hodgkin lymphoma, Chronic lymphocytic leukemia						US	Chordia
ONO-8250	iPSC-derived HER2 CAR T-cell therapy	HER2-expressing Solid tumor						US	Fate

★Combination with Nivolumab

Other than oncology

As of 22 July, 2024

Product Name	Mechanism	Target Disease	Development Stage					Country / Region	Licensor
			1	2	3	Filing	Approval
ONO-4059	BTK inhibitor	Pemphigus						JP	In-house
ONO-2910	Enhancement of Schwann cell differentiation	Diabetic polyneuropathy						JP	In-house
								US
		Chemotherapy-Induced Peripheral Neuropathy						JP	In-house
ONO-2808	S1P5 receptor agonist	Multiple System Atrophy						JP・US	In-house
ONO-4685	PD-1 x CD3 bispecific antibody	Autoimmune disease						JP・EU	In-house
ONO-2020	Epigenetic Regulation	Neurodegenerative disease						US	In-house
ONO-1110	Endocannabinoid regulation	Pain						JP	In-house